Galapagos NV operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Galapagos NV with three other
miscellaneous service companies in Europe:
sales of 3.03 billion Danish Kroner [US$447.05 million]
of which 100%
Bachem Holding AG
(282.50 million Swiss Francs [US$283.35 million]
of which 89%
was Active Pharmaceutical Ingredients), and
based in Sweden
(2.48 billion Swedish Kronor [US$253.12 million]
of which 58%
Galapagos NV reported sales of 317.85 million Euro (US$350.82 million)
December of 2018.
increase of 103.9%
versus 2017, when the company's sales were 155.92 million Euro.
This was the third consecutive year of growth at Galapagos NV.
Sales of R&d saw an increase
135.6% in 2018, from
118.26 million Euro to 278.67 million Euro.